BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2021.

Baxter International Inc., a leading global medical products company, will present at the UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 in Laguna Beach, Calif.

Bioasis Technologies Inc. announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2021.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2021.

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for monogenic diseases, announced that it will report its financial results for the second quarter and first six-month period ending June 30, 2021, on Thursday, August 5, 2021, after the close of the US market.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) — granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Thursday, August 5, 2021, at 8:30 a.m. ET.

Dyadic International, Inc. announced that it will report its financial results for quarter ended June 30, 2021 and host a corporate update conference call on Thursday, August 12, 2021.

Nuvo Pharmaceuticals Inc. (TSX: NRI) (OTCQX: NRIFF) d/b/a Miravo Healthcare (“Miravo” or the “Company”), today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC trading as Miravo Healthcare (“Miravo Ireland”), has entered into an exclusive license and supply agreement (the “License Agreement”) with SK Chemicals Co., Ltd. (“SK Chemicals”).

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and PeptiDream, Inc. (Tokyo Stock Exchange: 4587), announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.